ArticleNature genetics2022
Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection.
Open access · hybridAbstract read
In one paragraph
Article in Nature genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 2 pooled it
14.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs.Nature genetics · 2022Pooled it
- GPNMB promotes double-membrane vesicle accumulation and facilitates structural protein transport during PEDV infection.Virulence · 2026Article
- Mucins and Respiratory Virus Infection.Annual review of virology · 2026Review
- Cadherin 1 negatively regulates SARS-CoV-2 infection in the olfactory epithelium.EMBO reports · 2026Article
- Lock out: targeting TMPRSS2 to block influenza and coronaviruses.Journal of virology · 2026Review
- Parallel Activation and Interference CRISPR (PAIR) with Sequencing Uncovers DNA Repair Networks Guiding Precision Cell Engineering.bioRxiv : the preprint server for biology · 2026Article
- From CRISPR functional genomics to synthetic interventions: engineering antiviral strategies.Journal of virology · 2026Review
- Review
- Interactys-AI: Toward AI-Driven Structural Mapping of Virus-Host Interfaces for Antiviral Repurposing and Pandemic Preparedness.Biomolecules · 2026Review
- Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Elucidating genes sufficient for viral entry into cells through sequential genome-wide CRISPR activation screens.bioRxiv : the preprint server for biology · 2026Article
- SAMHD1 depletion restricts SARS-CoV-2 infection by suppressing HNF1-dependent ACE2 expression in lung epithelial cells.PLoS pathogens · 2026Article
- FGFR signaling and neddylation facilitate SARS-CoV-2 infection by modulating interferon induction and viral entry, respectively.iScience · 2026Article
- CRISPR-Cas9 Screening and Simulated Infection Transcriptomic Identify Key Drivers of Innate Immunity in Bactrian Camels.Animals : an open access journal from MDPI · 2026Article
- Host Responses to SARS-CoV-2 with an Emphasis on Cytokines.International journal of molecular sciences · 2026Review
- Functional Genomic Screening Identifies lncRNA CNPY2-AS1 as a Regulator of Redox Metabolism and Antiviral Immunity.International journal of biological sciences · 2026Article
- SARS-CoV-2-host and interactions: the dual roles of E3 ubiquitin ligases and ubiquitin-like modification mechanisms in viral infection.Frontiers in immunology · 2026Review
- Meta-analysis of functional genomics studies reveals conserved cellular pathways required by viruses of pandemic concern.Access microbiology · 2026Article
- T-Cell Immune Dysfunction and Progression to Severe COVID-19 in Asthma Revealed by Single-Cell RNA Sequencing.Tuberculosis and respiratory diseases · 2026Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 13 institutions in 1 country.
Scott B Biering *Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0003-1991-629X
Sylvia A Sarnik *Department of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-0466-5806
Eleanor WangDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.
James R ZengelDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Sarah R LeistDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-4760-4923
Varun SathyanDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-7929-4344
Padraig HawkinsMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kenichi OkudaMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9341-2730
Cyrus TauDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-7462-5431
Aditya R JangidDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.
Connor V DuffyDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
Jin WeiDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2832-1610
Rodney C GilmoreMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mia Madel AlfajaroDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.
Madison S StrineDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.
Xammy Huu WrynlaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
Erik Van DisDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.
Carmelle CatamuraCenter for Computational Biology, University of California, Berkeley, Berkeley, CA, USA.
Livia H YamashiroDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
Julia A BelkDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
Adam BegemanDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-5458-8610
Jessica C StarkDepartment of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3828-5438
D Judy ShonDepartment of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA, USA.
Douglas M FoxDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
Shahrzad EzzatpourDepartment of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Emily HuangMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nico OlegarioMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Arjun RustagiDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6921-1012
Allison S VolmerMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alessandra Livraghi-ButricoMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Eddie WehriThe Henry Wheeler Center for Emerging and Neglected Diseases, Berkeley, CA, USA.
Richard R BehringerDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dong-Joo CheonDepartment of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, NY, USA.
Julia SchaletzkyThe Henry Wheeler Center for Emerging and Neglected Diseases, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-7437-4684
Hector C AguilarDepartment of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Andreas S PuschnikChan Zuckerberg Biohub, San Francisco, CA, USA.
Brian ButtonMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Benjamin A PinskyDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-8751-4810
Catherine A BlishDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6946-7627
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6827-8701
Wanda K O'NealMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Carolyn R BertozziDepartment of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4482-2754
Craig B WilenDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2495-9403
Richard C BoucherMarsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jan E CaretteDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5187-8070
Sarah A StanleyDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA. eharris@berkeley.edu.ORCID http://orcid.org/0000-0002-7238-4037
Silvana KonermannDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA. silvanak@stanford.edu.ORCID http://orcid.org/0000-0001-7915-1685
Patrick D HsuDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA. pdhsu@berkeley.edu.ORCID http://orcid.org/0000-0002-9380-2648
University of North Carolina at Chapel Hill · USStanford University · USUniversity of California, Berkeley · USInnovative Genomics Institute · USYale University · USChan Zuckerberg Initiative (United States) · USCornell University · USAlbany Medical Center Hospital · USBerkeley Public Health Division · USHoward Hughes Medical Institute · USPalo Alto Institute · USThe University of Texas MD Anderson Cancer Center · USYale Cancer Center · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MVector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Martina Gentzsch · 2004 to 2026
$26.5MThe Biophysics of Mucus Hydration and Adhesion/CohesionP01HL108808 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEDEN, DAVID B. · 2012 to 2021
$23.9MPurinergic Control of CFTR-ENaC Interactions in Alveolar EpitheliaP01HL110873 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2012 to 2016
$10.7MEMERGING INFECTIOUS DISEASEST32AI007502 · NIAID · STANFORD UNIVERSITY · PI Prasanna Jagannathan, DAVID A. RELMAN · 1995 to 2026
$6.8MSynthesis of Effective and Safe Mucolytics for Pulmonary DiseaseUH3HL123645 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2016 to 2018
$4.6MMechanisms of Nipah virus fusion and entryR01AI109022 · NIAID · WASHINGTON STATE UNIVERSITY · PI AGUILAR-CARRENO, HECTOR · 2014 to 2024
$4.3MGenetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative CrossR01AI157253 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, HEISE, MARK T · 2020 to 2024
$3.8MInvestigating the Surface GlycoproteomeR01CA200423 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2015 to 2026
$3.8MMultiscale Biochemical/Biophysical Integration of Pulmonary Mucus TransportR01HL136961 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2017 to 2020
$3.2MThe role of mucus and pulmonary surface interactions in lung defenseR01HL125280 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUTTON, BRIAN M · 2015 to 2023
$3.1MEukaryotic transcriptome engineering via sequence-specific regulation of endogenous RNADP5OD021369 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI HSU, PATRICK · 2015 to 2018
$2.4MHoward Hughes Medical InstituteNCI NIH HHS F32 CA250324NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA200423NHLBI NIH HHS P01 HL108808NHLBI NIH HHS P01 HL110873NHLBI NIH HHS R01 HL125280NHLBI NIH HHS R01 HL136961NHLBI NIH HHS UH3 HL123645NIAID NIH HHS K08 AI128043NIAID NIH HHS K08 AI163369NIAID NIH HHS R01 AI109022NIAID NIH HHS R01 AI140186NIAID NIH HHS R01 AI141970NIAID NIH HHS R01 AI157253NIAID NIH HHS R21 AI156731NIAID NIH HHS T32 AI007502NIDDK NIH HHS P30 DK065988NIH HHS DP5 OD021369
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a range of symptoms in infected individuals, from mild respiratory illness to acute respiratory distress syndrome. A systematic understanding of host factors influencing viral infection is critical to elucidate SARS-CoV-2-host interactions and the progression of Coronavirus disease 2019 (COVID-19). Here, we conducted genome-wide CRISPR knockout and activation screens in human lung epithelial cells with endogenous expression of the SARS-CoV-2 entry factors ACE2 and TMPRSS2. We uncovered proviral and antiviral factors across highly interconnected host pathways, including clathrin transport, inflammatory signaling, cell-cycle regulation, and transcriptional and epigenetic regulation. We further identified mucins, a family of high molecular weight glycoproteins, as a prominent viral restriction network that inhibits SARS-CoV-2 infection in vitro and in murine models. These mucins also inhibit infection of diverse respiratory viruses. This functional landscape of SARS-CoV-2 host factors provides a physiologically relevant starting point for new host-directed therapeutics and highlights airway mucins as a host defense mechanism.
Indexed as
COVID-19AnimalsClustered Regularly Interspaced Short Palindromic RepeatsEpigenesis, GeneticHumansMiceMucinsSARS-CoV-2Mucins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.